Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement
Lee H, Blumberger D, Lenze E, Anderson S, Barch D, Black K, Cristancho P, Daskalakis Z, Eisenstein S, Huang Y, Li S, Lissemore J, McConathy J, Mulsant B, Rajji T, Reynolds C, Su Y, Tu Z, Voineskos D, Karp J. Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement. Biological Psychiatry Global Open Science 2021, 2: 127-135. PMID: 36325158, PMCID: PMC9616305, DOI: 10.1016/j.bpsgos.2021.09.003.Peer-Reviewed Original ResearchTranscranial magnetic stimulation measuresTreatment-resistant depressionPositron emission tomographyFunctional magnetic resonanceTarget engagementClinical trialsCortical transmissionMontgomery-Ã…sberg Depression Rating ScalePlacebo-controlled clinical trialEmission tomographyLow-dose augmentationVenlafaxine extended releasePrimary outcome measureBlood oxygen level-dependent (BOLD) responseMajor depressive episodeDepression Rating ScaleExperimental therapeutic approachesYears of ageMultimodal assessmentLevel-dependent responsesMonetary incentive delay taskBrain positron emission tomographyPlacebo groupIncentive delay taskClinical effects